Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177-Lu-DOTA-cG250
- Development stage
- Phase 2
- Lead developer
- Telix Pharmaceuticals
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Administration
- Intravenous
01
Overview
177-Lu-DOTA-cG250 is a radiolabeled chimeric monoclonal antibody targeting carbonic anhydrase IX (CAIX), a protein highly expressed in renal cell carcinoma. The drug consists of the cG250 antibody conjugated to the chelator DOTA and labeled with the beta-emitting radionuclide lutetium‑177. Upon administration, it binds specifically to CAIX-expressing tumor cells and delivers targeted ionizing radiation to induce tumor cell death while sparing surrounding healthy tissue. It is being developed primarily for advanced or metastatic renal cell carcinoma and has been evaluated in phase I/II clinical trials for safety, dosimetry, and preliminary efficacy[1][2][5][8].
- Brand names
- TLX250TLX-250TLX 250
- Other names
- 177-Lutetium-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-cG250Lu-177-DOTA-girentuximabLu177-DOTA-girentuximabLu 177-DOTA-girentuximabTLX-250TLX250TLX 250
02
Targets
CA9 (Carbonic anhydrase IX)
Beyond the preview
Go deeper on 177-Lu-DOTA-cG250.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177-Lu-DOTA-cG250.